Dossier
blood cancers
Coverage of blood cancers in the Nexus archive.
Centreorganization1Drugs Rules, 1945topic1cell and gene therapiestopic1stem cell-derived productstopic1regenerative treatmentstopic1CAR-T cell therapiestopic1leukemiastopic1lymphomastopic1National Medical Products Administrationorganization1BeOneorganization1sonrotoclaxtopic1Chinaplace1biotech boomtopic1innovative drugstopic1
- Centre amends Drugs Rules, 1945 to ensure uniform regulation of advance cell and gene therapies
The Centre has amended the Drugs Rules, 1945 to establish uniform regulation for advanced cell and gene therapies, including stem cell-based regenerative treatments and CAR-T cell therapies. These therapies are increasingly used to treat blood cancers like leukemias and lymphomas, and the amendment aims to strengthen regulatory oversight of emerging medical technologies.
- China’s drug regulator clears wave of home-grown innovative medicines amid biotech boom
China’s National Medical Products Administration (NMPA) approved 19 innovative drugs in 2024, with 15 developed by domestic companies, highlighting the country’s biotech growth. Notable approvals include sonrotoclax by BeOne for treating adult blood cancers, as the regulator streamlines its approval process.